Performance of Systane PRO Versus Refresh Optive Mega-3

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-15

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Single site, prospective, double-masked, randomized-controlled, cross-over study of the subjective and objective performance of 2 different eyedrops. Subjects will be assessed at a screening visit, and 3 follow-up visits. Clinical evaluations will include patient questionnaires.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Subjective and Objective Performance of Systane Complete Multi-Dose PF Versus Walgreen's Lubricant Balance

NCT06219577

Dry Eye

COMPLETED PHASE4

The Clinical Performance of Two Reusable Silicone Hydrogel Contact Lenses

NCT05766787

Refractive Ametropia

COMPLETED NA

Senofilcon A Lenses in Moderate to Severe Dry Eye Disease

NCT04096898

Moderate to Severe Dry Eye Disease

UNKNOWN NA

Comparison of Frequency of Use of Optive and Systane

NCT00406510

Dry Eye

COMPLETED PHASE4

Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes

NCT00796926

Xerophthalmia Blepharitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Systane PRO then Refresh Optive Mega-3

Group Type OTHER

Systane PRO

Intervention Type DRUG

Lubricating Eyedrops

Refresh Optive MEGA-3

Intervention Type DRUG

Lubricating Eyedrops

Refresh Optive Mega-3 then Systane PRO

Group Type OTHER

Systane PRO

Intervention Type DRUG

Lubricating Eyedrops

Refresh Optive MEGA-3

Intervention Type DRUG

Lubricating Eyedrops

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Systane PRO

Lubricating Eyedrops

Intervention Type DRUG

Refresh Optive MEGA-3

Lubricating Eyedrops

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who currently have moderate symptoms of dry eye as defined by a baseline OSDI score of 23-32 inclusive.
* Subjects between ages of 18-65 inclusive.
* Subjects who do not currently wear contact lenses.
* Subjects willing to fill out a daily diary during the duration of the study.
* Subjects willing to comply with the prescribed regimen and schedule of eye drops.
* Subjects willing to attend all study visits.

Exclusion Criteria

* Have an ophthalmologic diagnosis of: allergy, viral or bacterial conjunctivitis, anterior blepharitis, parasitic infestations in any ocular structure or its adnexa, unresolved ocular trauma, ocular surface scarring diseases, corneal or conjunctival ulcers, filamentous keratitis, neurotrophic keratitis, bulous keratopathy, neoplastic diseases on the ocular surface or adnexa, diseases with fibrovascular proliferations on the conjunctival and/or corneal surface, retinal and/or posterior diseases that require treatment or threaten the visual prognosis, or glaucoma.
* Eyelid disorders that cause eyelid malposition, limit adequate eyelid closure or opening or cause epiphora.
* History of herpetic keratitis or ocular surgery.
* Have dry eye management that requires the implementation of any treatments (except artificial tears) of stage 2 of the recommendations in the treatment and management by stages for the dry eye disease of the TFOS DEWS I\| (Tear Film and Ocular Surface Society Dry Eye Workshop I).
* Have a history of drug addiction or drug dependence currently or within the last two years before signing the ICF.
* Have another medical condition, acute or chronic, that in the opinion of the investigator could increase the risk associated with participation in the study or the administration of the investigational product, or that could interfere with the interpretation of the results of the study.
* Pregnant or lactating.
* Current use of contact lenses.
* Have participated in another clinical research study ≤30 days before screening visit.
* Any use of eye drops, whether OTC or Rx, in last 14 days.
* Subjects who have previously used either investigational product in the past.
* Have known hypersensitivity to the components of the investigational product.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No